? T cell function depends on a finely orchestrated balance of activation/suppression signals. While the stimulatory role of the CD8 co-receptor and pleiotropic capabilities of TGF-b have been studied individually, the influence of CD8 co-receptor on TGF-b function in CD8
Introduction

CD8 is a surface glycoprotein on CD8
? T cells (CTLs) which participates as a co-receptor in the CTL:antigen presenting cell (APC) interaction by binding the a3 domain of class I major histocompatibility complex (MHC-I) [1] . CD8 co-receptor in CTLs has been ascribed dual function (1) increasing CTL:APC adhesion and T cell receptor (TCR):peptide-loaded MHC-I (TCR:pMHC-I) affinity [2] ; and (2) signaling through Src-family tyrosine kinase Lck promoting its recruitment to the TCR/CD3 complex [3, 4] , leading to second messenger signaling and gene transcription-induced cytokine production, cell activation, and proliferation [5] .
Transforming growth factor-b (TGF-b) is a pleiotropic cytokine with regulatory activity affecting T cell proliferation, differentiation, and survival [6, 7] . Its activity is associated with self-tolerance, inflammation resolution, regulatory T cell/Th17 differentiation, and tumor-induced immuno-suppression, while its absence in mice results in lethal autoimmune disease [8] [9] [10] . TGF-b function is initiated by its binding to cell-surface TGF-b receptor II (TGF-b-RII) which phosphorylates TGF-b receptor I (TGF-b-RI) [11] . This complex phosphorylates transcription factors SMAD2/3, which bind SMAD4, translocate into the nucleus, and regulate gene transcription [12, 13] .
TGF-b signaling inhibition occurs through (1) SMAD7 inhibition of SMAD2/3 and (2) SMAD7-associated SMURF2 degradation of TGF-b receptors [14] .
While CD8 co-receptor and TGF-b have been individually studied, information on the influence of CD8 signaling on the effects of TGF-b on CD8
? T cells is lacking. We show here that while CD8-Lck signaling enhances T cell activation, it also enhances susceptibility to TGF-b-mediated suppression in human and mouse. These findings reveal an unappreciated role for CD8 co-receptor in balancing activation\suppression of CD8
? T cell function and highlight a TGF-b-mediated mechanism for cell contraction relevant to cancer immunology.
Methods
Cell lines and mice
The Jurkat-FHCRC cell line (clone E6-1) was obtained from ATCC (Manassas, VA). Jurkat cells are human T cell lymphoma established from the peripheral blood of a 14-year-old boy [15] . Jurkat cells require two signals for activation, TCR signaling and a phorbol ester (i.e. phorbol myristate acetate, PMA), for maximal IL-2 production. Jurkat cells expressing tyrosinase-specific TCR and abCD8, a 0 b 0 CD8 or no CD8 were prepared as described [16] . T2 cells are a Tap-1 -/-human B/T cell lymphoma. Cells were maintained in RPMI (Mediatech, Inc., Manassas, VA) with 10% heat-inactivated FBS (Atlanta Biologicals, Lawrenceville, GA), 2% penicillin/streptomycin and 2 mM L-glutamine (Mediatech). Experiments using eight-week-old, specific-pathogen-free, C57BL/6 and C57BL/ 6-Tg(TcraTcrb)1100Mjb/J (OT-I) mice (Jackson Laboratories, Bar Harbor, ME) were conducted according to Institutional Animal Care and Use Committee (IACUC) guidelines.
Human IL-2 ELISA ELISA was performed as per manufacturer protocols (eBioscience, San Diego, CA). T2 cells were peptide-loaded (2 h) with tyrosinase 368-376 or MART-1 [27] [28] [29] [30] [31] [32] [33] [34] [35] , washed twice, and cocultured with Jurkat cells and 50 ng/ml PMA (18-24 h, 1:1 ratio). Indicated cultures were treated with 50 ng/ml TGF-b (full-length, recombinant human TGF-b2 expressed in E. coli and reactive in human and mouse cells; EMD Chemicals, Inc., Gibbstown, NJ).
Mouse cell in vitro culture
Splenocytes were obtained after mechanical dissolution and red blood cell lysis and treated ± anti-CD3/CD28
antibodies (6-24 h ). Some cells were pre-treated with Lck Inhibitor (4-Amino-5-(4-phenoxyphenyl)-7H-pyrrolo[3,2-d]pyrimidin-7-yl-cyclopentane; 50 ng/ml or 1 lg/ml, EMD Chemicals). Indicated cultures were treated with 50 ng/ml TGF-b (full-length, recombinant human TGF-b2 expressed in E. coli and reactive in human and mouse cells; EMD Chemicals, Inc., Gibbstown, NJ). 
Statistical analyses
Student's t test (two-tailed) was used to calculate the P value. P \ 0.05 was considered statistically significant.
Results
CD8 expression impacts the susceptibility of Jurkat T cells to TGF-b-mediated suppression
It is unknown how the adhesion and signaling functions of CD8 impact TGF-b action on CD8
? T cells [2] . Using antibodies to block CD8 can lead to either stimulation or suppression [17] ; therefore, to determine the role of CD8 in conferring susceptibility to TGF-b-mediated suppression, we employed the use of the human Jurkat cell line. Jurkat cells are amenable to gene modification [18] [19] [20] , and the similarity of their signaling characteristics to primary human T cells is well described [21] . Specifically, in our study, Jurkat cells were transduced to express the tyrosinase 368-376 -specific TCR and (1) complete abCD8 (''abCD8''); (2) truncated abCD8 (''a 0 b 0 CD8'') with fulllength extracellular, but deleted intracellular portion; and (3) no CD8 (''CD8 -''); as described [16] . Both a 0 b 0 CD8 and ''a 0 b 0 CD8'' Jurkat cells expressed similar CD8 levels (Supplemental Fig. 1A ). Jurkat cells were cocultured (18 h) with tyrosinase 368-376 or irrelevant (MART-1 [27] [28] [29] [30] [31] [32] [33] [34] [35] ) peptide-loaded T2 cells and PMA (50 ng/ml). To indicated cultures 50 ng/ml TGF-b, a concentration similar to that found in healthy donor serum was added after 1 h of incubation. Because Jurkat cells secrete IL-2 following antigen stimulation [21, 22] , supernatants were assayed for IL-2 by ELISA. Expression of a 0 b 0 CD8 on Jurkat cells resulted in slight reduction in IL-2 compared with ''abCD8'' Jurkat cells and significant reduction by CD8 -Jurkat cells (Fig. 1a) . Addition of TGF-b induced strong reduction in IL-2 by CD8-expressing Jurkat cells. Greatest suppression was consistently observed in abCD8 versus a 0 b 0 CD8 Jurkat cells (64.4% versus 30.8% suppression, respectively; Fig. 1b ). Even at highest suppression levels, IL-2 was above background (Fig. 1a , dashed line) and above IL-2 from Jurkat cells not expressing tyrosinasespecific TCR or cocultured with MART-1 [27] [28] [29] [30] [31] [32] [33] [34] [35] peptideloaded targets (data not shown). Interestingly, CD8
-Jurkat cells were resistant to TGF-b-mediated suppression (Fig. 1a-b) . To determine whether inhibition of CD8 downstream signaling-associated molecule, Lck, would result in similar resistance, abCD8 Jurkat cells were cocultured with tyrosinase 368-376 -loaded T2 cells, PMA (50 ng/ml), and 50 ng/ml TGF-b (added after 1 h of coculture) ± Lck inhibitor (50 ng/ml, added 30 min prior to coculture). Addition of the Lck inhibitor decreased TGFb-mediated suppression (88-61%) (Supplemental Fig. 1B ). These data demonstrate that CD8 inversely regulates Jurkat T cell responsiveness to TGF-b.
Lck inhibition reduces mouse primary CD8 T cell susceptibility to suppression by TGF-b
To determine whether the effect of CD8 signaling on TGFb suppression observed using Jurkat cells translated to primary CD8
? T cells, mouse spleen CD8 ? T cells were activated in vitro with aCD3/aCD28 (1 lg/ml) antibodies ± Lck inhibitor (50 ng/ml or 1 lg/ml, present 30 min prior to and throughout culture) ± TGF-b (50 ng/ml, added 30 min into and throughout culture). Similarly, to test resistance in a peptide-stimulated mouse model, OT-I mouse splenocytes (OVA 257-264 transgenic) were stimulated with OVA 257-264 (1 lg/ml) ± Lck inhibitor ± TGF-b. Since CTL granzyme B is inhibited by TGF-b at the mRNA level [23] , we measured its production by intracellular flow cytometry (Fig. 1c) Supplemental Fig. 1B, CD8 ? T cells incubated with Lck inhibitor were highly resistant to TGFb-mediated suppression (Fig. 1d-e and Supplemental Fig. 2A-B) . While granzyme B production by CD8
? T cells not treated with Lck inhibitor was significantly reduced by TGF-b, Lck inhibitor-treated CD8
? T cells showed less resistance to TGF-b-mediated suppression of granzyme B. CD8
? T cells treated with 1 lg/ml Lck inhibitor were completely resistant to TGF-b-mediated suppression. Analogous to the lack of CD8 co-receptor in CD8-Jurkat cells, blocking of CD8 signaling via administration of a CD8-blocking monoclonal antibody (clone 2.43.1) showed decreased granzyme B production in mouse CD8
? T cells and such blocking of CD8 signaling decreased susceptibility of such CD8
? T cells to TGF-bmediated suppression (data not shown). Together these data support the findings that CD8-Lck signaling inversely regulates T cell responsiveness to TGF-b-mediated suppression. [7] , which are induced by abTCR activation. To determine whether resistance to TGF-b-mediated suppression observed was mediated by the level of receptor expression, TGF-b receptors I\II and abTCR expression was determined. Receptors levels were similar among activated CD8 -, abCD8, and a 0 b 0 CD8 Jurkat cells (Fig. 2a ) and likewise among activated mouse CD8
CD8 T cell susceptibility to TGF-b correlates with Smad levels but not TGF-b receptor I, TGF-b receptor II, abTCR or Lck expression TGF-b-mediated suppression is dependent on T cell detection of TGF-b through TGF-b receptors I and II
? T cells ± Lck inhibitor ( Fig. 2b and Supplemental Fig. 2C-D) . Additionally, CD8
? T cells expressed similar Lck levels ± TGF-b treatment, while inhibition of Lck via a pharmacological inhibitor decreased Lck signaling but not Lck expression in mouse CD8
? T cells (Supplemental Fig. 2E ) and Jurkat cells (data not shown). Therefore, the observed CD8-mediated resistance to suppression by TGFb was not due to variability in TGF-b-RI, TGF-b-RII, abTCR or Lck expression.
To determine whether CD8 alters TGF-b signaling pathways, we examined the impact of stimulation on Smad3 (TGF-b signal propagator) and Smad7 (TGF-b signal inhibitor) in Jurkat cells and Lck-inhibited OT-I CD8
? T cells after activation. CD8
-Jurkat cells had the greatest expression of Smad7 and the least expression of Smad3 levels; a 0 b 0 CD8 Jurkat cells had moderate expression of Smad7 and moderate expression in Smad3 levels; and abCD8 Jurkat cells had the lowest expression of Smad7 and highest expression of Smad3 levels ( Fig. 2c-d) . Similarly, Cancer Immunol Immunother (2011) 60:291-297 293
OT-I CD8 ? T cells with 1 lg/ml Lck inhibition had had the greatest expression of Smad7 and the least expression of Smad3 levels; OT-I CD8
? T cells with 50 ng/ml Lck inhibition had moderate expression of Smad7 and moderate expression of Smad3 levels; and OT-I CD8
? T cells without Lck inhibition had the lowest expression Smad7 and the greatest expression of Smad3 levels (Supplemental Figs. 2F-G) . These results suggest that the signaling function of CD8 (through Lck) impacts TGF-b-mediated suppression by altering the TGF-b signaling pathway. 
Discussion
We describe here a previously unappreciated role of the CD8 co-receptor in regulating CD8
? T cell susceptibility to TGF-b. While TGF-b is released from suppressioninducing cells (e.g. Treg cells), its action upon target cells involves the target's susceptibility to TGF-b. Our study assigns such susceptibility mediation role to the CD8 coreceptor and its intracellular signaling partner, Lck. Specifically, we demonstrate that elimination of CD8-Lck signaling (by CD8 truncation/elimination or Lck inhibition) decreases susceptibility of human and mouse CD8
? T cells to TGF-b-mediated suppression of effector cytokine production. Interestingly, in the absence of exogenous TGF-b treatment, intracellular CD8 truncation itself does not significantly decrease IL-2 but does significantly reduce Jurkat cell susceptibility to TGF-b. Though in these cells CD8 truncation lead to a disconnection between Lck and the CD8 co-receptor, Lck may have been activated via an alternative pathway, including signaling through alternative molecules on Jurkat cells, including CD45 [24, 25] . This finding highlights an important role for adhesion of CD8 to MHC-I, where such adhesion increases IL-2 production but also contributes to CD8
? T cell susceptibility to TGF-b-mediated suppression. Additionally, complete elimination of CD8 significantly decreases IL-2 as well as further reduces Jurkat cell susceptibility to TGF-b. IL-2 production by CD8
-Jurkat cells was still considerably above background, TCR and antigen control conditions, as well as above TGF-b-treated abCD8 Jurkat IL-2 production levels, indicating that increased suppression would be possible if these cells were further susceptible to TGF-b-mediated suppression. While there is some evidence that human and mouse CD8 co-receptor is dispensable in T cell:APC adhesion [26, 27] , our findings add evidence to studies [28, 29] demonstrating a significant adhesion role for CD8 co-receptor in CD8
? T cells. Our findings also indicate that TCR-pMHC interaction itself is vital and in the context of high affinity TCR-pMHC interaction can overcome deletion of CD8-Lck interaction, ? T cells after 4-h culture with anti-CD3/CD28 mAbs (1 lg/ml) ± Lck inhibitor (1 lg/ml). c Smad3 levels after 30-min coculture (as described in a). D, Smad7 levels after coculture (as described in c).*P \ 0.05, **P \ 0. ? T cells to overcome a TGF-b-induced unresponsiveness threshold and become activated [30] . Essentially, this study mimics the ability of cells to overcome TGF-b suppression after stimulation (i.e. like a naive cell overcomes TGF-b upon specific\sufficient activation). In our hands, CD8:Lck has similar affects when TGF-b is added prior to activation (personal observation); however, our study expands on the understanding of Lck signaling effects by showing a reciprocal function for Lck signaling after the addition of TGF-b in cells that have already been activated (i.e., like an effector cell reacts to an activationinduced increase in TGF-b). Therefore, in testing two different scenarios, both findings accurately describe T cell responses to temporally separated combinations of activation and inhibition signals.
Our While our proposed third role for CD8 (conferring susceptibility to TGF-b) may seem to contrast with widely accepted activation-inducing CD8 functions, such action by CD8-Lck may in essence define a negative-feedback mechanism by which CD8
? T cells control the magnitude\timing of effector response. During CD8
? T cell expansion, there is a parallel, but delayed, increase in TGFb which after surpassing a threshold leads to contraction in non-resistant cells. Based on our findings here, further study may be warranted into the effect of TGF-b in high versus low affinity/avidity CD8:APC interactions and the role of CD8:Lck signaling in modulating the response of these cells to TGF-b-mediated suppression. Likewise, based on the direct role which tumor-induced TGF-b mediates suppression of tumor antigen-specific CD8
? T cell function, these findings unveil necessary considerations in formulation of CD8
? T cell-related cancer immunotherapy strategies.
